trial

Cannabidiol Treatment in Patients With Early Psychosis

NCTId NCT02504151
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 18 (actual)
Sponsored by Yale University
Primary completion 2018-03-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
18 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2016-01-28
Primary completion
2018-03-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Cannabidiol

Sponsors

Yale UniversityLead Sponsor

Sites

2 total
New Haven, United StatesWest Haven, United States

Linked catalysts

1
Cannabidiol Treatment in Patients With Early Psychosis — primary completion2018-03-02

Facts & assertions

4 sourced
Enrollment
18
Phase
PHASE2
Primary Completion Date
2018-03-02
Status
COMPLETED
relationships
The graph out of here
drug
Cannabidiol
drug
lead_sponsor
Yale University
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication